Dittrich, T., Hansen, T., Kimmich, C., Veelken, K., Jauch, A. S., Raab, M., . . . Schönland, S. (2025). Elotuzumab in combination with dose reduced IMiDs and dexamethasone for AL amyloidosis patients with relapsed/refractory plasma cell dyscrasia and advanced organ involvement. American journal of hematology, 100(6), . https://doi.org/10.1002/ajh.27684
Chicago Style (17th ed.) CitationDittrich, Tobias, Timon Hansen, Christoph Kimmich, Kaya Veelken, Anna Sophia Jauch, Marc-Steffen Raab, Carsten Müller-Tidow, Ute Hegenbart, and Stefan Schönland. "Elotuzumab in Combination with Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients with Relapsed/refractory Plasma Cell Dyscrasia and Advanced Organ Involvement." American Journal of Hematology 100, no. 6 (2025). https://doi.org/10.1002/ajh.27684.
MLA (9th ed.) CitationDittrich, Tobias, et al. "Elotuzumab in Combination with Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients with Relapsed/refractory Plasma Cell Dyscrasia and Advanced Organ Involvement." American Journal of Hematology, vol. 100, no. 6, 2025, https://doi.org/10.1002/ajh.27684.